Similarly, lack of collagen specificity characterizes the most recent anti–TGF-β antibody treatment that is in clinical trials as an inhibitor of the tumor microenviroment and metastasis and as a bone mineral density inducer for OI (49). This evidence concerns the gene TGFB1 and neoplasm.